logo
Size matters? Unpacking penile surgery trends in Korea

Size matters? Unpacking penile surgery trends in Korea

Korea Herald26-07-2025
From 'sunflower' techniques to fat grafting, penile enlargement has evolved into one of the most sought-after male sexual surgeries in Korea — but risks remain
Lim, a 30-year-old office worker, was taken aback when she first saw her new boyfriend's altered anatomy.
He had undergone surgery to insert silicone implants in the shape of beads or rings beneath the skin of the glans, transforming the penis into a sunflower-like shape, commonly known as Sunflower Surgery or T-Ring Surgery here.
"I was surprised, but it was a good surprise — a positive one," she remarked.
This surgery is primarily used to increase girth and enhance sexual pleasure by allowing the implants to rub against the vaginal walls during intercourse, delivering intense orgasmic sensations, according to Lim.
Historically, bigger has not always meant better. Some cultures preferred a more compact member.
According to research by historian Paul Chrystal, the ancient Greeks associated smaller penises with their ideals of male beauty, viewing them as symbols of sophisticated culture and civilization. This perspective is highlighted in Chrystal's book "In Bed with the Ancient Greeks."
Despite these historical exceptions, penile enlargement continues to be one of the most common sexual surgeries pursued by men in Korea today.
For many, size does indeed matter. Men are often subjected to societal pressures — both explicit and implicit — that suggest small is shameful, frequently making penis size a subject of humor and jokes.
Perhaps due to this backdrop, Korean men show keen interest in penile enlargement surgeries, and many, like 35-year-old office worker surnamed Ha, report undergoing such procedures.
'I had penile enlargement surgery, and I am a former army non-commissioned officer. Most of my unit's peers, juniors and seniors also had it done.'
Ha underwent the sunflower surgery about 10 years ago. Prices for the basic procedure start at around 500,000 won ($365), with additional features costing more.
Ha, who declined to offer his full name, expressed satisfaction with the procedure, stating, "My girlfriends are satisfied, and my former colleagues say their wives and girlfriends are satisfied too."
However, he noted occasional discomfort, feeling as if foreign objects were lodged inside.
Another individual, a 25-year-old university student using the pseudonym Kim Min-jae, underwent penile enlargement surgery at a urology clinic in Gangnam, Seoul, last year.
Kim explained that his motivation for the surgery stemmed from a painful personal experience.
"I happened to see an Instagram DM exchange a few years ago, between my then-girlfriend and her friend discussing their sexual experiences with their partners," he said.
"She mentioned that mine was significantly smaller than her previous boyfriends' and that she couldn't feel much pleasure with me. Discovering this by chance on her phone was devastating and led me to a point of depression."
Determined to address his perceived inadequacy, Kim measured his penis and found that while his length was within the average range, his girth was about 1 cm less than average.
This realization prompted him to consider surgery. He opted for a "fat grafting" procedure, also known as fat transfer phalloplasty, which involves extracting fat from areas like the inner thigh or abdomen, purifying it, transferring it into syringes and evenly injecting it into the penile shaft to increase girth.
"Immediately after the surgery, my girth increased by 1.5 to 2 centimeters, and after six months, it stabilized at about 1 centimeter more. Although the pain when waking from anesthesia was intense, I've since felt much less self-conscious," Kim said.
Dr. Lee Haeng-nam, a specialist in urology, stated, "Using one's own fat eliminates the risk of allergic reactions, leading to a lower likelihood of complications. Due to these advantages, four out of five patients seeking penis enlargement surgery, regardless of age, choose this procedure and report high satisfaction."
The benefits of this procedure are supported by a study published in Aesthetic Plastic Surgery in September 2011, which reported an overall patient satisfaction rate of 92 percent and a satisfaction rate regarding the shape of 90 percent. The study found an average increase in penile girth of 2.3 cm post-surgery, according to Lee.
Lee also noted that while this procedure is beneficial for the general population, individuals with naturally small penises or micropenis conditions may find particularly high satisfaction levels.
According to Lee, the average penile girth for Korean men is between 6 to 7cm when flaccid, but 25 percent of Korean men either have a "micropenis" — less than 4 cm — or experience dissatisfaction, known as micropenis complex.
These procedures, however, come with reports of ineffectiveness or severe side effects.
The American Urological Association warns that most penile enlargement techniques are ineffective and risky, citing complications such as ineffective fat injections, unsafe ligament divisions and various surgical risks.
An anonymous individual recently shared his experience on the online forum DC Gallery about undergoing augmentation with dermal substitutes in Korea.
He described enduring severe pain, incurring costs of 4 million won to 5 million won, and experiencing inflammation, which ultimately required the removal of the dermal substitutes.
"Before the surgery, my flaccid length was 5cm, and when erect, it was 11cm with a 10cm girth. After the surgery, there was only a slight increase in flaccid length, but I encountered relentless pain. Remember that satisfaction varies greatly between individuals; think twice before deciding.'
jenn@heraldcorp.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Is using a sun umbrella linked to racial bias?
Is using a sun umbrella linked to racial bias?

Korea Herald

timea day ago

  • Korea Herald

Is using a sun umbrella linked to racial bias?

Parasols, or sun umbrellas, have long been a summer necessity in several Asian countries. It is easy to spot both men and women holding them over their heads in the streets of South Korea and Japan, to shield against the sunlight and strong UV rays. However, a viral TikTok video claiming that the widespread use of such sunshades in Asia stems from underlying "white supremacy" has stirred controversy and sparked heated debates over whether the issue is about racism or health. In the video, titled 'Asians afraid of being dark," the TikToker questions why parasols are so popular in Asian countries. 'Someone needs to explain to me why Asians are so afraid of the sun,' she said. "I promise you it's not that bad if you go a little darker ... A few minutes in the sun won't make your skin that dark.' She then went on to imply that the fear of darker skin tones among Asians is linked to the bias of 'white supremacy,' suggesting that such aversion stems from internalized ideals of lighter skin as superior. The video has garnered over 600,000 views and more than 6,200 comments, many of which strongly push back against the assertion. One commenter wrote, 'I get headaches from just a short time in the sun. I don't care about getting darker. I just don't want to pass out in the street.' Another user asked, 'If I get skin cancer, are you going to pay my hospital bills?' Others called out the oversimplification of health-conscious behavior as racial bias. 'Avoiding sunburn and skin cancer is not white supremacy.' Experts have weighed in as well, emphasizing that UV umbrellas can be vital tools for sun protection, especially during record-breaking heat waves and intense ultraviolet radiation. Dermatologists note that parasols can help prevent sunburn, premature aging, sunspots and even hair loss by shielding areas such as the face, neck and scalp from direct sunlight. Science supports these claims: according to a joint study by the Seoul Institute and Japan's Ministry of the Environment, the use of parasols can lower the perceived temperature by up to 10 degrees Celsius. By blocking direct rays and diffusing radiant heat, parasols create a shaded microclimate, reducing the risk of heat-related illnesses such as heatstroke. Sunshades also offer eye protection by minimizing glare and reducing the risk of cataracts and macular degeneration. Prolonged exposure to UV rays can also contribute to skin aging and, in severe cases, skin cancer. Proper parasol selection is key. Experts recommend choosing umbrellas with a white outer layer to reflect light and a dark-coated inner layer to absorb residual rays. Like sunscreen, their effectiveness wanes over time; parasols should be replaced every two to three years or when the UV coating deteriorates. As summer heat intensifies, more people are relying on parasols for protection. Sales data from major Korean department stores also show a sharp rise in parasol purchases. From July 1 to 29, Shinsegae reported a 44.3 percent increase in sunshade sales compared to the same period last year. Lotte and Hyundai department stores recorded jumps of 60 percent and 47 percent, respectively. Interestingly, even in the US, where sunshades have traditionally been seen as niche accessories, parasols are gaining mainstream attention. The New York Post recently dubbed UV umbrellas the "hottest summer trend," reporting that many Americans are turning to them for relief in increasingly oppressive weather.

Daewoong's Nabota hits record H1 sales, expands to Middle East
Daewoong's Nabota hits record H1 sales, expands to Middle East

Korea Herald

time2 days ago

  • Korea Herald

Daewoong's Nabota hits record H1 sales, expands to Middle East

South Korean drugmaker Daewoong Pharmaceutical announced Thursday that its botulinum toxin product, Nabota, posted 115.4 billion won ($83 million) in revenue in the first half of this year, up 28 percent from last year. With this growth, Daewoong expects to surpass 200 billion won in annual sales this year. Nabota was approved by the US Food and Drug Administration in 2019 as the first Asian botulinum toxin. Since then, Daewoong has pursued a premium strategy focused on high purity, high safety and strict quality control standards. Nabota is now sold under the brand name Jeuveau in the US, the world's largest aesthetics toxin market, where it holds a 14 percent market share in the aesthetics segment, ranking second overall. Daewoong also continues to grow in Latin America and Southeast Asia, following major deals previously signed in Brazil and Thailand. The company recently signed a deal with Kuwait, expanding its reach to five Middle Eastern countries, including the UAE, Saudi Arabia and Qatar — the widest regional coverage among Korean toxin brands. Alongside product expansion, Daewoong is promoting its proprietary injection technique, Nabolift, through global training programs, aiming to enhance medical outcomes and brand presence. 'Nabota is now a global top-tier brand in aesthetics,' said Yoon Joon-soo, head of Daewoong Pharmaceutical's Nabota Business Division. 'We will strengthen our global leadership with premium quality and scientific proof.'

OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure
OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure

Korea Herald

time2 days ago

  • Korea Herald

OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure

BELLEVUE, Wash. and SEOUL, South Korea, July 31, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today issued a strategic update regarding its recently announced Term Sheet with Woori IO Co., Ltd. ("WORIO"), a South Korean medical device company pioneering noninvasive glucose monitoring technology. The transaction, once completed, will result in WORIO becoming a wholly owned subsidiary of OSR Holdings Co., Ltd. ("OSRK"), a Korean affiliate of OSRH. As previously disclosed, WORIO shareholders will receive newly issued OSRK shares, along with a conditional right to exchange those shares for OSRH common stock if OSRH's share price reaches $10.00 or more within three years from the signing of the Term Sheet. WORIO Shareholders Align with OSRH Upside The company emphasizes that the $10 OSRH share condition is intended as a performance-aligned incentive, reflecting WORIO shareholders' long-term confidence in OSRH's growth potential. Rather than requesting immediate liquidity, the Sellers — WORIO's shareholders — have agreed to convert their OSRK shares into OSRH shares only upon OSRH reaching $10.00 per share, representing a nearly 10x premium over recent trading levels. "This is not a dilution event, but a strong vote of confidence," said Peter Hwang, CEO of OSR Holdings. "WORIO's shareholders are betting on our ability to realize transformative value and are choosing to stay aligned with OSRH shareholders for the long term. That alignment is a positive signal for the market." If OSRH's share price does not meet the $10.00 threshold within three years, the conversion will not occur, and WORIO shareholders will remain equity holders in the privately held OSRK entity. The companies have agreed to renegotiate in good faith at that time, if necessary. Noninvasive Glucose Monitoring: A Transformational Market The strategic rationale behind the transaction lies in the tremendous unmet need and market potential for noninvasive glucose monitoring. Today's global CGM (continuous glucose monitoring) market — dominated by companies like Dexcom and Abbott — still relies on minimally invasive sensors that require skin penetration or consumables. WORIO's technology leverages near-infrared spectroscopy (NIRS) to deliver accurate, needle-free glucose measurement. This makes it well suited for integration into wearable devices such as smartwatches. The company has already completed a proof-of-concept study at Korea University Hospital and is now preparing for a larger confirmatory study for regulatory approval in Korea. "WORIO gives OSRH a unique opportunity to enter this global market before the technology reaches commercial maturity," added Mr. Hwang. "This transaction positions our shareholders to benefit from a future that could redefine diabetes management — without the burden of invasive devices." Industry Landscape and Strategic Positioning According to industry reports, the global blood glucose monitoring device market is projected to exceed $40 billion by 2030, with strong tailwinds from rising diabetes prevalence and increasing demand for painless, real-time monitoring. "Imagine the difference this technology could make for individuals who face the daily burden of monitoring blood glucose and navigating the complexity of current invasive devices," said Dr. Constance Höfer, CSO of OSRH. "Beyond the clear advantages for patients and their caregivers, this new non-invasive device could also generate valuable novel datasets—for example, in patients at early stages of metabolic syndrome, studies on cancer relapse and the benefits of exercise, or research exploring the effects of pre- and probiotics on human health and the optimization of elite athletic performance." To date, no company worldwide has received regulatory approval for truly noninvasive glucose monitoring. Media coverage of startups like Afon Technology in Europe underscore the growing interest and momentum in this field, yet few players have established both a working prototype and a regulatory engagement plan. WORIO represents one of the rare companies globally to meet both criteria — and OSRH is positioned as an early acquirer ahead of full commercialization. In Q1 2025, WORIO was selected to participate in Samsung Electronics' innovative startup program, C-Lab Outside. Next Steps Under the 6-month exclusivity period set forth in the Term Sheet, OSRH will continue confirmatory legal, financial, and technical due diligence, with a target to execute definitive agreements within that window. The company looks forward to further engaging with investors as this transaction develops. About OSR Holdings, Inc. OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device technologies. Its vision is to build a portfolio of breakthrough healthcare solutions to improve global health outcomes. Learn more at About Woori IO Co., Ltd. Woori IO is a South Korea-based medical device company developing noninvasive biosensing technologies for glucose monitoring and beyond. Its proprietary NIRS-based system enables accurate, pain-free glucose tracking and is designed for integration into wearables. Visit for more information. Forward-Looking Statements This press release contains forward-looking statements, including expectations regarding the proposed acquisition of Woori IO, future stock performance, regulatory approvals, and market potential. These statements are based on current assumptions and involve risks and uncertainties that could cause actual results to differ materially. OSR Holdings undertakes no obligation to update these statements except as required by law.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store